Corxel Pharmaceuticals to go public in U.S. via SPAC merger with Amanat
Corxel Pharmaceuticals is pursuing a U.S. public listing through a merger with special purpose acquisition company Amanat Acquisition Corp. The transaction is expected to provide about $377 million, including a $300 million private investment from institutional investors, as the obesity drug developer advances its lead oral candidate.
Highlights
- Corxel Pharmaceuticals will go public on Nasdaq via merger with Amanat Acquisition Corp, targeting a deal close in first half of 2027.
- Corxel expects to raise approximately $377 million from the SPAC transaction and concurrent PIPE, with $300 million already committed by institutional investors.
- Lead candidate CX11, targeting obesity and type 2 diabetes, is advancing toward late-stage development amid intensifying competition in cardiometabolic treatments.
Deal structure and development plans
As reported by Reuters, Corxel Pharmaceuticals says it will go public in the U.S. through a merger with Amanat Acquisition Corp, in a deal that is anticipated to close in the first half of 2027. The combined company is expected to list on the Nasdaq.Corxel is expected to receive roughly $377 million from the SPAC transaction and a concurrent private investment in public equity. Institutional investors have committed $300 million to the PIPE financing.
The company is developing oral product candidates, with lead candidate CX11 targeting obesity, type 2 diabetes and related cardiometabolic conditions. Work is continuing to move the candidate into late-stage development.
Financing context and sector implications
A SPAC is a shell company that raises money through an initial public offering and then uses those funds to merge with or acquire a private company, allowing the target to enter public markets without a traditional IPO. For Corxel, the route provides access to capital as competition in obesity and metabolic disease treatments continues to intensify.Leerink Partners is serving as lead placement agent for the PIPE financing. Evercore ISI, Guggenheim Securities, Cantor and LifeSci Capital are also acting as placement agents.
Our earlier Nasdaq 100 outlook noted that the index was rebounding as investors positioned ahead of major earnings and potential Federal Reserve decisions, supporting near-term risk appetite in tech shares. It also highlighted mixed momentum signals and a likely consolidation range, with 28,991 identified as a key support level and 29,632 as a breakout point to watch for the next directional move.
Latest Pharmaceutical Industry News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
